tiprankstipranks
Trending News
More News >
Medmira Inc (TSE:MIR)
:MIR
Advertisement

Medmira (MIR) AI Stock Analysis

Compare
38 Followers

Top Page

TSE:MIR

Medmira

(MIR)

Rating:43Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Medmira's overall stock score is heavily influenced by its poor financial performance, which poses significant risks. Technical analysis and valuation further emphasize the challenges, despite positive corporate events suggesting potential strategic improvements.

Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)

Medmira Business Overview & Revenue Model

Company DescriptionMedmira Inc. (MIR) is a healthcare company specializing in the development and manufacturing of rapid diagnostic tests. The company operates in the medical diagnostics sector, offering innovative testing solutions that deliver immediate results. Medmira's core products include tests for infectious diseases such as HIV, hepatitis, and syphilis, among others. These products are designed to be user-friendly and provide quick, accurate results, making them suitable for use in various healthcare settings.
How the Company Makes MoneyMedmira makes money through the sale of its rapid diagnostic testing products to healthcare providers, clinics, and laboratories. The company's revenue model primarily revolves around direct sales and distribution agreements with partners in different regions. Medmira also engages in licensing agreements, where it provides its proprietary technology to third-party manufacturers or distributors. Significant partnerships with healthcare organizations and government entities further contribute to its earnings, as these collaborations often lead to bulk purchase agreements and expanded market reach. Additionally, Medmira may receive funding from research grants and initiatives aimed at enhancing public health diagnostic capabilities.

Medmira Financial Statement Overview

Summary
Medmira faces significant financial challenges, with declining revenue growth, negative gross profit margin, and negative net profit margin. The balance sheet shows high leverage and negative equity, while cash flow analysis reveals negative free cash flow and reliance on external funding.
Income Statement
20
Very Negative
Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.
Balance Sheet
15
Very Negative
The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.
Cash Flow
25
Negative
Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue412.57K432.53K952.13K2.14M919.07K
Gross Profit226.49K-434.91K304.03K1.72M572.28K
EBITDA-2.13M-1.58M-1.07M185.30K-1.13M
Net Income-3.33M-2.68M-1.83M-675.80K-2.05M
Balance Sheet
Total Assets6.07M3.65M3.83M3.89M3.40M
Cash, Cash Equivalents and Short-Term Investments2.10M13.18K33.46K-2.30M401.86K
Total Debt9.56M9.27M8.30M11.54M11.91M
Total Liabilities24.11M18.68M16.19M19.61M18.96M
Stockholders Equity-18.04M-15.03M-12.36M-15.72M-15.56M
Cash Flow
Free Cash Flow-3.68M-1.27M-1.95M-541.19K-417.78K
Operating Cash Flow-2.94M-1.27M-1.88M-504.64K-315.90K
Investing Cash Flow-742.53K-1.27K-69.72K-36.55K-101.88K
Financing Cash Flow5.77M1.25M1.99M139.32K730.74K

Medmira Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.08
Negative
100DMA
0.09
Negative
200DMA
0.09
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
7.79
Positive
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 7.79 is Positive, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
C$71.84M18.6214.51%28.97%
66
Neutral
C$41.47M25.435.32%-4.67%-60.94%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
43
Neutral
C$147.80M-211.24%0.10%
43
Neutral
C$52.32M
-33.66%-48.89%
33
Underperform
C$57.48M248.46%32.71%
33
Underperform
C$77.12M685.26%-50.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:MIR
Medmira
0.08
0.00
0.00%
TSE:ONC
Oncolytics Biotech
1.53
0.11
8.13%
TSE:HBP
Helix BioPharma
1.04
-0.31
-22.96%
TSE:COV
Covalon Technologies
2.62
0.54
25.96%
TSE:SVA
Sernova
0.20
-0.07
-25.93%
TSE:MBX
Microbix Biosystms
0.29
-0.03
-9.38%

Medmira Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada
Positive
Jul 7, 2025

MedMira has launched a clinical trial for its Multiplo® TP/HIV self-test in Canada, marking a significant step in addressing the rising cases of HIV and syphilis in the country. The trial, supported by Health Canada and funded by the Canadian Institutes of Health Research, aims to bring the self-test to communities in need, bypassing traditional regulatory steps. This initiative is expected to empower individuals with privacy and control over their health, potentially reducing the spread of these infections by providing immediate results and facilitating access to care.

Product-Related AnnouncementsFinancial DisclosuresRegulatory Filings and Compliance
MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing
Positive
Jul 1, 2025

MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025